Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 5/20 | 0.51 |
| ▸ | CASP1 | P29466 | 3/20 | 0.51 |
| ▸ | CASP9 | P55211 | 3/20 | 0.51 |
| ▸ | CASP4 | P49662 | 2/20 | 0.51 |
| ▸ | CASP5 | P51878 | 2/20 | 0.51 |
| ▸ | CASP6 | P55212 | 2/20 | 0.51 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.51 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 7/20 | 0.49 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28714127 | 1.00 | REN (0.52) | RENCASP3CASP1CASP9CASP4 | |
| SCHEMBL17814784 | 1.00 | REN (0.52) | RENCASP3CASP1CASP9CASP4 | |
| SCHEMBL20257265 | 0.94 | CASP3 (0.57) | RENCASP3CASP1CASP9CASP4 | |
| SCHEMBL21481085 | 0.94 | CASP3 (0.57) | RENCASP3CASP1CASP9CASP4 | |
| SCHEMBL29612356 | 0.94 | CASP3 (0.57) | RENCASP3CASP1CASP9CASP4 | |
| SCHEMBL23133287 | 0.94 | CASP3 (0.57) | RENCASP3CASP1CASP9CASP4 | |
| SCHEMBL23133285 | 0.94 | CASP3 (0.57) | RENCASP3CASP1CASP9CASP4 | |
| SCHEMBL23613622 | 0.90 | CASP3 (0.56) | RENCASP3CASP1CASP9CASP4 | |
| SCHEMBL23133260 | 0.89 | REN (0.51) | RENCTSBCTSLCTSSCTSK | |
| SCHEMBL29946166 | 0.89 | REN (0.51) | RENCTSBCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100055-A1 | METHODS OF TREATING HEMATOLOGIC CANCERS | BIOCRYST PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-20220040188-A1 | METHODS OF TREATING HEMATOLOGIC CANCERS | BIOCRYST PHARMACEUTICALS, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100055-A1 | METHODS OF TREATING HEMATOLOGIC CANCERS | PNP, TYMP, NTPCR | REN 2807/4885CASP3 1014/4885CASP1 1903/4885 |
| US-20220040188-A1 | METHODS OF TREATING HEMATOLOGIC CANCERS | PNP, TYMP, NTPCR | REN 2807/4885CASP3 1014/4885CASP1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.